FDA Approves Durvalumab for Muscle Invasive Bladder Cancer By Ogkologos - May 2, 2025 899 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the NIAGARA study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR Beating the Heat with Beets July 31, 2020 FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... September 24, 2024 New on NCI’s Websites for December 2021 December 29, 2021 Junk food marketing restrictions: so near and yet so far December 15, 2022 Load more HOT NEWS SARS-CoV-2 Antibodies Can Protect from Reinfection, NCI Study Suggests Five Questions With…Linda. The UK Government’s spending review: Time to invest in the future... No Benefit for Post-operative Radiotherapy in Non-small-cell Lung Cancer [ESMO2020 Press...
